SC pulls up Centre over soaring medicine costs

The Supreme Court expressed concern over the government's role in allowing steep medicine prices to persist. Justices Vikram Nath and Sandeep Mehta questioned the justification for significant price discrepancies faced by patients. The court highlighted a lack of accountability regarding how drug manufacturers benefit from inflated prices. Government representatives stated that regulatory measures should not encompass the entire drug pricing ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WKD2ST4
via IFTTT

Read More

Cipla sets sights on first-wave gains from rollout of Keytruda Biosimilar

Cipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for this drug is expected to expire around 2029, allowing for potential market entry. Cipla anticipates capturing a significant share of this lucrative market segment after the launch. Additionally, the company reported a 35% decline in consolidated net profit in the September quarter.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/q27gIB0
via IFTTT

Read More

Healthware partners Fujifilm to expand use of precision surgical imaging solutions

Healthware has entered a partnership with Fujifilm to expand the use of intra-operative ultrasound systems across India. This collaboration aims to meet the critical clinical needs in complex surgeries. Real-time surgical ultrasound will be made available in more operating rooms, enhancing the speed of surgical procedures. The partnership combines technological innovation with clinical expertise for better patient outcomes. Healthware's national service and support network will facilitate this advancement in healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/R63ECuB
via IFTTT

Read More

Cipla expects US business to draw support from upcoming product pipeline

Cipla reported a significant decline in its consolidated net profit for the second quarter of FY27. The company's North American revenue fell by 19% due to increased competition impacting sales of generic Revlimid. However, Cipla anticipates that its upcoming product pipeline will support performance in North America. In India, domestic revenue rose, providing some resilience amidst challenges in the US market.

from Healthcare/Biotech-Industry-Economic Times https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/cipla-expects-us-business-to-draw-support-from-upcoming-product-pipeline/articleshow/135229843.cms
via IFTTT

Read More

Sakar Healthcare posts Rs 11 cr profit in Q2

The company said the second quarter growth was supported by new oncology approvals, strong demand across geographies, a better oncology mix, operating leverage, and disciplined cost management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/atrA53o
via IFTTT

Read More

Mankind Pharma shares key business developments from Q2 & H1 of FY27

The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of 18.7% and 15.8%, respectively. In acute therapies, gastroenterology grew at 1.3 times the market rate, while vitamins, minerals and nutrients (VMN) expanded at 1.4 times that rate.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8DIvUoX
via IFTTT

Read More

Lord’s Mark Industries Limited becomes Asia’s first company to secure multiple US FDA registrations for 200+ surgical and hygiene products; US exports to begin in December

Silvassa manufacturing expansion completed ahead of schedule as the company prepares to expand its international footprint across the United States and South America

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z25eqPc
via IFTTT

Read More